MedImmune Lands Fast Track Status for Flu Candidate

AstraZeneca’s MedImmune unit has snagged fast track designation for MEDI8852, which is being assessed for treating patients hospitalized with Type A strain influenza.

The candidate is being evaluated in a Phase 1b/2a clinical trial investigating a single dose in combination with oseltamivir, and as a monotherapy in adult patients with confirmed acute, uncomplicated Type A influenza.